Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
& Nord, C.L
To view or add a comment, sign in Elevara Medicines Doses First Patient in Phase 2b START-SYNERGY Trial of ELV001 in RA Patients News from Towards Healthcare Elevara Medicines has reached a significant milestone by dosing the first patient in their Phase 2b START-SYNERGY trial of ELV001, a novel oral CDK4/6 inhibitor, aimed at rheumatoid arthritis (RA) patients with incomplete response to methotrexate (MTX) and TNF inhibitors
It mimics a natural hormone that regulates blood sugar and appetite, helping reduce food cravings and creating a feeling of fullness after meals
Potential Research Applications: Libido and sexual arousal pathway studies Central nervous system (CNS) melanocortin receptor research Neuroendocrine and behavioral response investigations Sexual function and arousal mechanism modeling For laboratory research use only
US$ 24.02
US$ 20.09
US$ 27.37
US$ 24.79
US$ 21.69
